CD19/BCMA-Targeted Chimeric Antigen Receptor-T Cell Therapy for Anti-HLA Antibody Sensitisation in Patients With Acute Leukaemia: A Pilot Clinical Study
Novel CAR-T cell therapy successfully removes dangerous antibodies before transplant in patients previously ineligible for life-saving bone marrow donation.
This pilot study of 7 acute leukemia patients (AML/B-ALL) demonstrates that CD19 and BCMA CAR-T cell therapy can effectively reduce anti-HLA antibodies pre-transplant, with 71% showing MFI decline and 43% achieving >75% reduction, without severe toxicity. The approach offers a novel desensitization strategy for HLA-sensitized patients who would otherwise be denied HSCT.
What the study was
- Study design
- Single-arm pilot clinical study
- Population
- 7 patients with acute leukaemia (4 AML, 3 B-ALL) awaiting HSCT with anti-HLA sensitization
- Sample size
- 7
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- HLA
Why it surfaced
First pilot study using CAR-T (CD19/BCMA) as a desensitization strategy for anti-HLA antibodies in AML/B-ALL patients awaiting transplant — a genuinely novel application of an approved therapeutic class to solve a critical transplant barrier. High unmet need; no grade ≥3 toxicity. Requires validation in larger cohort.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.